Science Explorer Interactive view Map
Company · Cambridge · United States

Infinity Pharmaceuticals (United States)

infi.comROR OpenAlex
Research works
115
▼ 81% vs 2013–17
Citations
7.2k
62.7 per fractional work
Top-10% rate
28.5%
record average 16.5%
Open access
26%
world 28%

Not ranked overall: Infinity Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.61× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 26.56× its world share, 0 worksImmunology and Micro…Chemistry: 1.54× its world share, 0 worksChemistryComputer Science: 0.19× its world share, 0 worksComputer ScienceMedicine: 2.96× its world share, 1 worksMedicinePsychology: 0.42× its world share, 0 worksPsychologySocial Sciences: 0.20× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 26.6×. Every wedge is a field page.

Which keywords describe research at Infinity Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Cancer, Prognostic Factors, Tumorigenesis, Development, Stem Cells, Rituximab and Pancreatic Cancer.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Therapy17▲ 24×11 topics
  2. Cancer16▲ 9.9×19 topics
  3. Prognostic Factors9▲ 18×9 topics
  4. Tumorigenesis8▲ 127×3 topics
  5. Development8▲ 20×4 topics
  6. Pancreatic Cancer8▲ 55×2 topics
  7. Rituximab8▲ 41×2 topics
  8. Stem Cells8▲ 22×4 topics
  9. Basal Cell Carcinoma7▲ 154×2 topics
  10. Hedgehog Signaling7▲ 172×1 topic
  11. Pathway Inhibition7▲ 353×1 topic
  12. Apoptosis7▲ 15×5 topics
  13. Mutation6▲ 36×2 topics
  14. Protein Folding6▲ 102×2 topics
  15. Molecular Chaperones6▲ 168×2 topics
  16. Therapeutic Targets6▲ 21×3 topics
  17. Innate Immunity6▲ 14×4 topics
  18. Chronic Lymphocytic Leukemia6▲ 99×1 topic
  19. Genomic Aberrations6▲ 99×1 topic
  20. Heat Shock Proteins5▲ 211×1 topic
  21. Proteostasis5▲ 97×1 topic
  22. Regulation5▲ 6.9×5 topics
  23. Tumor Microenvironment5▲ 12×7 topics
  24. Medicinal Chemistry5▲ 11×3 topics
  25. Proteasome Inhibitors4▲ 54×2 topics
  26. Metabolism4▲ 5.7×4 topics
  27. NF-?B Activation4▲ 67×2 topics
  28. PET Imaging4▲ 16×4 topics
  29. Tumor Suppression4▲ 30×2 topics
  30. Cell Cycle4▲ 59×1 topic
  31. p534▲ 79×1 topic
  32. Signaling4▲ 29×2 topics
  33. Drug Development4▲ 23×3 topics
  34. Molecular Docking4▲ 22×1 topic
  35. Virtual Screening4▲ 44×1 topic
  36. Pharmacology3▲ 8.9×5 topics
  37. Targeted Therapy3▲ 13×5 topics
  38. DNA Methylation3▲ 23×1 topic
  39. PI3K/AKT pathway3▲ 126×1 topic
  40. mTOR3▲ 126×1 topic

Which research topics does Infinity Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Xenotransplantation and immune response and CAR-T cell therapy research.

Monoclonal and Polyclona…0Monoclonal and Polyclonal Antibodies Research: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksXenotransplantation and immune response: 0 fractional worksCAR-T cell therapy research: 0 fractional worksT-cell and B-cell Immunology: 0 fractional worksChronic Lymphocytic Leuk…0Chronic Lymphocytic Leukemia Research: 0 fractional worksChronic Myeloid Leukemia Treatments: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksPhagocytosis and Immune …0Phagocytosis and Immune Regulation: 0 fractional works
Radiology, Nuclear Medicine and ImagingImmunologySurgeryOncology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  2. 2 Immunotherapy and Immune Responses Immunology 0 works
  3. 3 Xenotransplantation and immune response Surgery 0 works
  4. 4 CAR-T cell therapy research Oncology 0 works
  5. 5 T-cell and B-cell Immunology Immunology 0 works
  6. 6 Chronic Lymphocytic Leukemia Research Genetics 0 works
  7. 7 Chronic Myeloid Leukemia Treatments Hematology 0 works
  8. 8 Cancer Immunotherapy and Biomarkers Oncology 0 works
  9. 9 Phagocytosis and Immune Regulation Immunology 0 works
  10. 10 interferon and immune responses Immunology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available26.5%not open73.5%

World: 28% of research is openly available.

with international co-authors12.2%domestic only87.8%

World: 19% is written across borders.

How has Infinity Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 81% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Cambridge

All research institutions in Cambridge

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.